Esophageal candidiasis in human immunodeficiency virus-infected pediatric patients after the introduction of highly active antiretroviral therapy

Pediatric Infectious Disease Journal

Volumn 21, Issue 5, 2002, Pages 388-392

  Chiou, Christine C ^a   Groll, Andreas H ^a   Mavrogiorgos, Nikolaos ^a   Wood, Lauren V ^a   Walsh, Thomas J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Candida; Children; Esophagitis; Highly active antiretroviral therapy

Indexed keywords

ABACAVIR; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; AMPRENAVIR; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; CLOTRIMAZOLE; DIDANOSINE; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LAMIVUDINE; NELFINAVIR; NYSTATIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIAZOLE DERIVATIVE; VORICONAZOLE; ZALCITABINE;

ADOLESCENT; ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDA; CANDIDIASIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DYSPHAGIA; ESOPHAGUS DISEASE; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; MALE; NAUSEA; OROPHARYNX; PHARYNGITIS; PRIORITY JOURNAL; THRUSH; VIRUS LOAD; VOMITING; CD4 LYMPHOCYTE COUNT; INCIDENCE; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR;

ADOLESCENT; ANTIFUNGAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; CHILD; ESOPHAGEAL DISEASES; FEMALE; HIV INFECTIONS; HUMAN; INCIDENCE; MALE; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; HUMANS;

EID: 0035999342     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-200205000-00008     Document Type: Article

References (32)

1. Immune restoration with antiretroviral therapies: Implications for clinical management
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection: HIV Outpatient Study Investigators
3. Changing patterns of mortality across Europe in patients infected with HIV-1: EuroSIDA Study Group
4. Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy
5. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1
6. Esophageal candidiasis in pediatric acquired immunodeficiency syndrome: Clinical manifestations and risk factors
7. Natural history of human immunodeficiency virus disease in perinatally infected children: An analysis from the Pediatric Spectrum of Disease Project
8. Correlates of opportunistic infections in children infected with the human immunodeficiency virus managed before highly active antiretroviral therapy: The Pediatric AIDS Clinical Trials Group Protocol Teams 051, 128, 138, 144, 152, 179, 190, 220, 240, 245, 254, 300 and 327
9. A Phase I/II study of the protease inhibitor ritonavir in children with human immunodeficiency virus infection
10. A Phase I/II study of the protease inhibitor indinavir in children with HIV infection
11. Antifungal susceptibility testing: Practical aspects and current challenges
12. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1
13. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children
14. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children
15. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1-infected children: National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group
16. Clinical virologic and immunologic responses of children with advance HIV type 1 disease treated with protease inhibitors
17. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus
18. A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency type 1 disease treated with combination therapy including ritonavir
19. HIV-protease inhibitors reduce cell adherence of Candida albicans strains by inhibition of yeast secreted aspartic proteases
20. Current approaches to diagnosis and treatment of fungal infections in children infected with human immunodeficiency virus
21. Oropharyngeal candidiasis in patients with HIV: Suggested guidelines for therapy
22. Prevention of opportunistic Infections Working Group: 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus
23. Emergence of resistance of Candida albicans to clotrimazole in human immunodeficiency virus-infected children: In vitro and clinical correlations
24. Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis
25. Refractory mucosal candidiasis in advanced human immunodeficiency virus infection
26. Correlation between in vitro and in vivo antifungal activity in experimental fluconazole-resistant oropharyngeal and esophageal candidiasis
27. Clinical pharmacology of systemic antifungal agents: A comprehensive review of agents in clinical use, current investigational compounds, and putative targets for antifungal drug development
28. New drugs and novel targets for treatment of invasive fungal infections in patients with cancer
29. Dosage-dependent antifungal efficacy of the echinocandin VER-002 (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis
30. A randomized, double blind, multicenter trial of MK-0991 (L-743,872) vs. amphotericin B (AmB) in the treatment of Candida esophagitis in adults
31. Phase II, randomized, open label study of two intravenous dosing regimens of V-echinocandin in the treatment of esophageal candidiasis
32. A multicenter study of the echinocandin antifungal FK463 for the treatment of esophageal candidiasis in HIV positive patients